Dr. ReillyMichael Reilly, Ph.D.

Contact Dr. Reilly

1015 Walnut Street
Suite 701
Philadelphia, PA 19107

(215) 955-2768
(215) 923-3836 fax

Research and Clinical Interests
Dr. Reilly's research interests focus on platelet biology, the pathophysiology of immune thrombocytopenias and use of transgenic mouse models to gain a greater understanding of the molecular mechanisms of human diseases. Dr. Reilly, in collaboration with Dr. Steven McKenzie, created and characterized a transgenic mouse model of heparin-induced thrombocytopenia-thrombosis (HIT/T). HIT/T is the most frequent cause of drug-induced antibody-mediated thrombocytopenia, a common cause of life- and limb-threatening thrombosis. Although antibodies to heparin/PF4 complexes are found in essentially all patients with HIT/T, it is unclear how antibody formation is initiated, why only small subsets of these antibodies cause disease or the mechanism by which they initiate thrombosis.

Publications

Most recent Peer-reviewed Publications

  1. The clot thickens (or not)
  2. Heparin-induced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly
  3. Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles
  4. Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model
  5. Platelet FcγRIIA binds and internalizes IgG-containing complexes
  6. PF4/heparin complexes are T cell-dependent antigens
  7. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia
  8. Heparin-induced thrombocytopenia and other immune thrombocytopenias: Lessons from mouse models
  9. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin
  10. Mechanisms of action of IVIg: physiology of Fc receptors.
  11. Insights from mouse models of heparin-induced thrombocytopenia and thrombosis
  12. Paradoxical relationship between immune thrombocytopenia and glomerulonephritis in spontaneously autoimmune FcγRIIA transgenic mice
  13. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcγRIIA
  14. Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus
  15. Cilostazol: Treatment of intermittent claudication
  16. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model demonstrates the requirement for human platelet factor 4 and platelet activation through fcyriia
  17. Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia
  18. Thrombosis and shock induced by activating antiplatelet antibodies in human FcγRIIA transgenic mice: The interplay among antibody, spleen, and Fc receptor
  19. The role of the human Fc receptor FcγRIIA in the immune clearance of platelets: A transgenic mouse model
  20. Effect of an allosteric modifier of hemoglobin, RSR-4, on oxygen affinity and oxygen saturation of hemoglobin in rabbits

View All Publications